Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Freese, P.
Right arrow Articles by Nyberg, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freese, P.
Right arrow Articles by Nyberg, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 2401-2406
© 2001 European Renal Association-European Dialysis and Transplant Association

Chronic allograft nephropathy—biopsy findings and outcome

Poul Freese1, Christian T. Svalander2, Johan Mölne2, Gunnela Nordén3 and Gudrun Nyberg3,

1 Department of Nephrology, Rigshospitalet, Copenhagen, Denmark, 2 Department of Pathology, Sahlgrenska University Hospital and 3 Transplant Unit, Sahlgrenska University Hospital, Göteborg, Sweden

Background. Chronic allograft nephropathy (CAN) is a composite term for various types of damage to a kidney transplant. We wanted to analyse its components in relation to baseline biopsy findings, transplant function, and outcome.

Methods. Among renal transplantations performed from 1985 to 1997, 156 were identified where allograft biopsies had been obtained on clinical indication 6 months after transplantation or later, baseline biopsies were available in each case and the patient's original disease was known. Time after transplantation was median 2.2 years (range 0.5–13). The biopsies were reviewed and the Banff 1997 CAN score obtained.

Results. All but one late biopsy showed some CAN grade, 48% grade II, and 7.5% grade III. Acute tubulointerstitial rejection was seen in 9% but vascular rejection in only 3%. Arterial wall thickening was present in 66% of the late biopsies, correlated with donor age and its presence at baseline but also with time after transplantation. The Banff CAN score and serum creatinine level were both independent predictors of further graft survival, relative risk 0.35 (confidence interval 0.15–0.82, P=0.015) for CAN grade I vs III and 0.30 (0.14–0.67, P=0.003) for serum creatinine <170 vs >250 µmol/l. Presence of arterial wall thickening had no prognostic impact.

Conclusion. The CAN grade is predictive of further graft survival independently of the serum creatinine level. Interstitial fibrosis and tubular atrophy are more prominent features of chronic graft damage than vascular rejection. Unspecific arterial wall thickening is partly dependent on baseline conditions and lacks prognostic impact in this late stage.

Keywords: Banff criteria; chronic rejection; graft survival; renal allograft biopsy

Correspondence and offprint requests to: G. Nyberg, MD, PhD, Transplant Unit, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. Email: gudrun.nyberg{at}medic.gu.se


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.